Community Practice Considerations: Emerging Bispecific Antibodies in NHL

Podcast 2: Outcomes of key clinical trials in management of NHL

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Which of the following CD20/CD3 bispecific antibodies has been approved for use in patients with refractory/relapsed follicular lymphoma in Europe? 
For which of the following novel therapies in DLBCL is peripheral neuropathy a commonly reported toxicity? 
Each of the following is a commonly reported adverse event in clinical trials evaluating glofitamab except: 
A 67-year-old man presents with multistation adenopathy, fever, and drenching night sweats. A biopsy reveals he has non-GCB, DEL, normal FISH DLBCL. A PET-CT shows diffuse adenopathy above and below the diaphragm and extranodal involvement of lung, liver, and bone. An end-of-treatment PET-CT scan after six cycles shows CR, but 6 months after remission he develops firm swelling of the left knee and mid back pain. A PET-CT shows destructive mass of left knee as well as vertebral involvement with pathologic compression fracture and multifocal bony recurrence of disease in axial and appendicular skeleton, confirming DLBCL. He is treated with R-ICE and after two cycles shows a mixed response with some areas of progression. How would you treat this patient?
Powered by QuestionPro